(NASDAQ: INBX) Inhibrx Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.2%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.65%.
Inhibrx Biosciences's earnings in 2026 is -$130,185,000.On average, 4 Wall Street analysts forecast INBX's earnings for 2026 to be -$145,231,537, with the lowest INBX earnings forecast at -$145,934,287, and the highest INBX earnings forecast at -$142,647,941. On average, 4 Wall Street analysts forecast INBX's earnings for 2027 to be -$104,527,799, with the lowest INBX earnings forecast at -$110,277,437, and the highest INBX earnings forecast at -$97,049,895.
In 2028, INBX is forecast to generate -$59,462,317 in earnings, with the lowest earnings forecast at -$61,680,600 and the highest earnings forecast at -$56,335,887.